Literature DB >> 22644776

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.

Sebastian Stintzing1, Christine Kapaun, Rüdiger Paul Laubender, Andreas Jung, Jens Neumann, Dominik Paul Modest, Clemens Giessen, Nicolas Moosmann, Andreas Wollenberg, Thomas Kirchner, Volker Heinemann.   

Abstract

Skin toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) targeting agents. Occurrence of cetuximab-induced skin toxicity (Cet-ST) correlates with better treatment response and longer survival times. Molecular markers predicting Cet-ST are still missing. This investigation analyzed the value of Cet-ST for treatment efficacy in a randomized trial comparing cetuximab plus capecitabine/irinotecan to cetuximab plus capecitabine/oxaliplatin as first-line treatment of metastatic colorectal cancer. Patient characteristics and molecular parameters (KRAS mutation, EGFR-FISH, EGFR-IHC and EGFR intron-1 polymorphism) of the tumour were correlated with response and Cet-ST. Cet-ST grade 0-1 was observed in 31%, grade 2-3 in 69% of patients. Outcome favoured patients with grade 2-3 Cet-ST with regard to overall response rate (62 vs. 41%), PFS (7.8 vs. 5.2 months) and overall survival (OS) (30.3 vs. 18.0 months). First-cycle rash was observed in 66% of patients and corresponded with longer survival (30.7 vs. 20.2 months, p = 0.007). Patients without Cet-ST had a poor outcome (PFS, 1.9 months; OS, 11 months). The correlation of Cet-ST with survival was specifically evident in patients with KRAS codon-12-mutated tumours assumed to be cetuximab resistant. In multivariate analysis of patient characteristics, male gender and younger age were significantly correlated with Cet-ST. Among molecular parameters, no significant correlation with Cet-ST was found. Cet-ST is an early predictor of treatment efficacy in cetuximab-treated patients. This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644776     DOI: 10.1002/ijc.27654

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.

Authors:  T Kogawa; A Doi; M Shimokawa; T M Fouad; T Osuga; F Tamura; T Mizushima; T Kimura; S Abe; H Ihara; T Kukitsu; T Sumiyoshi; N Yoshizaki; M Hirayama; T Sasaki; Y Kawarada; S Kitashiro; S Okushiba; H Kondo; Y Tsuji
Journal:  Target Oncol       Date:  2014-05-27       Impact factor: 4.493

2.  Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Authors:  Carl Christoph Schimanski; Frank Staib; Thomas Göhler; Holger Hebart; Michael Heike; Michael Neise; Jochen Rudi; Thomas Geer; Gerrit Dingeldein; Claudia Lang; Peter Ehscheidt; Thomas Flohr; Klaus Maria Josten; Meinolf Karthaus; Alexander Schmittel; Jan Wierecky; Emil Boller; Martin Indorf; Marcus-Alexander Wörns; Peter R Galle; Markus Moehler
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-14       Impact factor: 4.553

3.  Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Authors:  Yu Sunakawa; Dongyun Yang; Miriana Moran; Stephanie H Astrow; Akihito Tsuji; Craig Stephens; Wu Zhang; Shu Cao; Takehiro Takahashi; Tadamichi Denda; Ken Shimada; Mitsugu Kochi; Masato Nakamura; Masahito Kotaka; Yoshihiko Segawa; Toshiki Masuishi; Masahiro Takeuchi; Masashi Fujii; Toshifusa Nakajima; Wataru Ichikawa; Heinz-Josef Lenz
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 4.  BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors.

Authors:  Catherine J Wang; Isaac Brownell
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

Review 5.  Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

Authors:  Christopher M Hocking; Timothy J Price
Journal:  Therap Adv Gastroenterol       Date:  2014-01       Impact factor: 4.409

Review 6.  The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.

Authors:  F Petrelli; K Borgonovo; S Barni
Journal:  Target Oncol       Date:  2013-01-16       Impact factor: 4.493

7.  The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity.

Authors:  Didem Tastekin; Makbule Tambas; Kemal Kilic; Kayhan Erturk; Deniz Arslan
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

8.  Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.

Authors:  Ken Nakata; Takamichi Komori; Kazuhiro Saso; Hirofumi Ota; Yoshinori Kagawa; Shunji Morita; Shingo Noura; Nobuyasu Hayashi; Mamoru Uemura; Chu Matsuda; Taroh Satoh; Tsunekazu Mizushima; Kohei Murata; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Int J Colorectal Dis       Date:  2021-08-03       Impact factor: 2.571

9.  EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.

Authors:  Rachel L Braden; Milan J Anadkat
Journal:  Support Care Cancer       Date:  2016-04-27       Impact factor: 3.603

Review 10.  Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.

Authors:  Akiko Kubo; Hironobu Hashimoto; Naoki Takahashi; Yasuhide Yamada
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.